Why is Ultragenyx stock plunging 45% today?

Ultragenyx stock plunged 44.7% in pre-open trading today, hitting $14.67, after the company disclosed late Wednesday that its pivotal Phase 3 Aspire study of apazunersen (GTX-102) in Angelman syndrome failed to meet its primary endpoint of change from baseline in Bayley-4 cognitive raw score, as well as the key secondary endpoint of net response in the Multidomain Responder Index.

Investigators found no meaningful differences between the treated and placebo groups on either measure, representing what analysts characterized as a decisive and clean trial failure for a drug that had been viewed as a cornerstone of the company’s pipeline.

The clinical setback immediately prompted a cascade of analyst actions on Thursday morning. Evercore ISI downgraded the stock from Outperform to In Line and slashed its price target from $34 to $16, while Baird moved from Outperform to Neutral with a target cut from $40 to $16, and JPMorgan lowered its rating from Overweight to Neutral, reducing its price target from $80 to $36.

William Blair also downgraded shares to Market Perform, stripping out the GTX-102 pipeline contribution entirely and flagging the company’s ongoing cash consumption and the longer-term risk of Crysvita losing exclusivity as additional headwinds.

The broader market offered no counterweight to the company-specific damage, with the S&P 500, Dow Jones, and Nasdaq each trading only fractionally higher, reflecting a largely neutral macro backdrop. There were no major central bank announcements or economic data releases that materially influenced biotech sentiment on the day.

The combination of a high-profile late-stage trial failure — eliminating what investors had priced as a significant probability of success in a disease with substantial unmet need — and a synchronized wave of institutional downgrades left the stock deeply pressured in pre-market trading, pushing shares toward their lowest levels in over a year and well beneath the 52-week low of $18.29 recorded in the prior period.